Compare EPR Properties (EPR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? EPR Properties trades at $54.64 (market cap $4.18B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: EPR Properties is far larger — about 4.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and EPR Properties pays a 6.82% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 48 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EPR | MRVI | |
|---|---|---|
Market Cap | $4.18B | $977.37M |
Volume | 699,137 | 2,742,564 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $9.00 |
52-Week Low | $48.71 | $2.83 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $7.69B | $1.08B |
Dividend Yield | 6.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $54.80, down 1.1% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The REIT shows strong profitability with a 91.41% gross margin and 37.66% net income margin, though net income dipped slightly in 2026. Recent news highlights its 6.5% dividend yield and focus on diversification beyond theaters into experiential properties, with Q3 2026 earnings due October 29, 2026.
The outlook is mixed: analyst consensus is a Buy with a $65.50 price target, implying ~20% upside, supported by a high yield and undervalued P/FFO. Risks include exposure to leisure and entertainment tenants, rising interest rates impacting financing costs, and the Q1 2026 earnings miss. Cash flow trends show a net outflow in 2026, warranting monitoring of dividend coverage.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
